Vaccination With Oral Polio Vaccine Reduces COVID-19 Incidence
Effective response to emerging pandemic threats is complicated by the need to develop specific vaccines and other medical products. The availability of broadly specific countermeasures that could be deployed early in the pandemic could significantly alter its course and save countless lives. Live at...
Uloženo v:
| Vydáno v: | Frontiers in immunology Ročník 13; s. 907341 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Frontiers Media S.A
30.05.2022
|
| Témata: | |
| ISSN: | 1664-3224, 1664-3224 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Effective response to emerging pandemic threats is complicated by the need to develop specific vaccines and other medical products. The availability of broadly specific countermeasures that could be deployed early in the pandemic could significantly alter its course and save countless lives. Live attenuated vaccines (LAVs) were shown to induce non-specific protection against a broad spectrum of off-target pathogens by stimulating innate immune responses. The purpose of this study was to evaluate the effect of immunization with bivalent Oral Poliovirus Vaccine (bOPV) on the incidence of COVID-19 and other acute respiratory infections (ARIs).BackgroundEffective response to emerging pandemic threats is complicated by the need to develop specific vaccines and other medical products. The availability of broadly specific countermeasures that could be deployed early in the pandemic could significantly alter its course and save countless lives. Live attenuated vaccines (LAVs) were shown to induce non-specific protection against a broad spectrum of off-target pathogens by stimulating innate immune responses. The purpose of this study was to evaluate the effect of immunization with bivalent Oral Poliovirus Vaccine (bOPV) on the incidence of COVID-19 and other acute respiratory infections (ARIs).A randomized parallel-group comparative study was conducted in Kirov Medical University. 1115 healthy volunteers aged 18 to 65 were randomized into two equal groups, one of which was immunized orally with a single dose of bOPV "BiVac Polio" and another with placebo. The study participants were monitored for three months for respiratory illnesses including COVID-19. The endpoint was the incidence of acute respiratory infections and laboratory confirmed COVID-19 in both groups during 3 months after immunization. The number of laboratory-confirmed cases of COVID-19 was significantly lower in the vaccinated group than in placebo (25 cases vs. 44, p=0.036). The difference between the overall number of clinically diagnosed respiratory illnesses in the two groups was not statistically significant.Methods and FindingsA randomized parallel-group comparative study was conducted in Kirov Medical University. 1115 healthy volunteers aged 18 to 65 were randomized into two equal groups, one of which was immunized orally with a single dose of bOPV "BiVac Polio" and another with placebo. The study participants were monitored for three months for respiratory illnesses including COVID-19. The endpoint was the incidence of acute respiratory infections and laboratory confirmed COVID-19 in both groups during 3 months after immunization. The number of laboratory-confirmed cases of COVID-19 was significantly lower in the vaccinated group than in placebo (25 cases vs. 44, p=0.036). The difference between the overall number of clinically diagnosed respiratory illnesses in the two groups was not statistically significant.Immunization with bOPV reduced the number of laboratory-confirmed COVID-19 cases, consistent with the original hypothesis that LAVs induce non-specific protection against off-target infections. The findings are in line with previous observations of the protective effects of OPV against seasonal influenza and other viral and bacterial pathogens. The absence of a statistically significant effect on the total number of ARIs may be due to the insufficient number of participants and heterogeneous etiology of ARIs. OPV could be used to complement specific coronavirus vaccines, especially in regions of the world where the vaccines are unavailable, and as a stopgap measure for urgent response to future emerging infections. Clinical trial registration number NCT05083039 at clinicaltrals.gov https://clinicaltrials.gov/ct2/show/NCT05083039?term=NCT05083039&draw=2&rank=1.ConclusionsImmunization with bOPV reduced the number of laboratory-confirmed COVID-19 cases, consistent with the original hypothesis that LAVs induce non-specific protection against off-target infections. The findings are in line with previous observations of the protective effects of OPV against seasonal influenza and other viral and bacterial pathogens. The absence of a statistically significant effect on the total number of ARIs may be due to the insufficient number of participants and heterogeneous etiology of ARIs. OPV could be used to complement specific coronavirus vaccines, especially in regions of the world where the vaccines are unavailable, and as a stopgap measure for urgent response to future emerging infections. Clinical trial registration number NCT05083039 at clinicaltrals.gov https://clinicaltrials.gov/ct2/show/NCT05083039?term=NCT05083039&draw=2&rank=1. |
|---|---|
| AbstractList | BackgroundEffective response to emerging pandemic threats is complicated by the need to develop specific vaccines and other medical products. The availability of broadly specific countermeasures that could be deployed early in the pandemic could significantly alter its course and save countless lives. Live attenuated vaccines (LAVs) were shown to induce non-specific protection against a broad spectrum of off-target pathogens by stimulating innate immune responses. The purpose of this study was to evaluate the effect of immunization with bivalent Oral Poliovirus Vaccine (bOPV) on the incidence of COVID-19 and other acute respiratory infections (ARIs).Methods and FindingsA randomized parallel-group comparative study was conducted in Kirov Medical University. 1115 healthy volunteers aged 18 to 65 were randomized into two equal groups, one of which was immunized orally with a single dose of bOPV “BiVac Polio” and another with placebo. The study participants were monitored for three months for respiratory illnesses including COVID-19. The endpoint was the incidence of acute respiratory infections and laboratory confirmed COVID-19 in both groups during 3 months after immunization. The number of laboratory-confirmed cases of COVID-19 was significantly lower in the vaccinated group than in placebo (25 cases vs. 44, p=0.036). The difference between the overall number of clinically diagnosed respiratory illnesses in the two groups was not statistically significant.ConclusionsImmunization with bOPV reduced the number of laboratory-confirmed COVID-19 cases, consistent with the original hypothesis that LAVs induce non-specific protection against off-target infections. The findings are in line with previous observations of the protective effects of OPV against seasonal influenza and other viral and bacterial pathogens. The absence of a statistically significant effect on the total number of ARIs may be due to the insufficient number of participants and heterogeneous etiology of ARIs. OPV could be used to complement specific coronavirus vaccines, especially in regions of the world where the vaccines are unavailable, and as a stopgap measure for urgent response to future emerging infections. Clinical trial registration number NCT05083039 at clinicaltrals.gov https://clinicaltrials.gov/ct2/show/NCT05083039?term=NCT05083039&draw=2&rank=1 Effective response to emerging pandemic threats is complicated by the need to develop specific vaccines and other medical products. The availability of broadly specific countermeasures that could be deployed early in the pandemic could significantly alter its course and save countless lives. Live attenuated vaccines (LAVs) were shown to induce non-specific protection against a broad spectrum of off-target pathogens by stimulating innate immune responses. The purpose of this study was to evaluate the effect of immunization with bivalent Oral Poliovirus Vaccine (bOPV) on the incidence of COVID-19 and other acute respiratory infections (ARIs).BackgroundEffective response to emerging pandemic threats is complicated by the need to develop specific vaccines and other medical products. The availability of broadly specific countermeasures that could be deployed early in the pandemic could significantly alter its course and save countless lives. Live attenuated vaccines (LAVs) were shown to induce non-specific protection against a broad spectrum of off-target pathogens by stimulating innate immune responses. The purpose of this study was to evaluate the effect of immunization with bivalent Oral Poliovirus Vaccine (bOPV) on the incidence of COVID-19 and other acute respiratory infections (ARIs).A randomized parallel-group comparative study was conducted in Kirov Medical University. 1115 healthy volunteers aged 18 to 65 were randomized into two equal groups, one of which was immunized orally with a single dose of bOPV "BiVac Polio" and another with placebo. The study participants were monitored for three months for respiratory illnesses including COVID-19. The endpoint was the incidence of acute respiratory infections and laboratory confirmed COVID-19 in both groups during 3 months after immunization. The number of laboratory-confirmed cases of COVID-19 was significantly lower in the vaccinated group than in placebo (25 cases vs. 44, p=0.036). The difference between the overall number of clinically diagnosed respiratory illnesses in the two groups was not statistically significant.Methods and FindingsA randomized parallel-group comparative study was conducted in Kirov Medical University. 1115 healthy volunteers aged 18 to 65 were randomized into two equal groups, one of which was immunized orally with a single dose of bOPV "BiVac Polio" and another with placebo. The study participants were monitored for three months for respiratory illnesses including COVID-19. The endpoint was the incidence of acute respiratory infections and laboratory confirmed COVID-19 in both groups during 3 months after immunization. The number of laboratory-confirmed cases of COVID-19 was significantly lower in the vaccinated group than in placebo (25 cases vs. 44, p=0.036). The difference between the overall number of clinically diagnosed respiratory illnesses in the two groups was not statistically significant.Immunization with bOPV reduced the number of laboratory-confirmed COVID-19 cases, consistent with the original hypothesis that LAVs induce non-specific protection against off-target infections. The findings are in line with previous observations of the protective effects of OPV against seasonal influenza and other viral and bacterial pathogens. The absence of a statistically significant effect on the total number of ARIs may be due to the insufficient number of participants and heterogeneous etiology of ARIs. OPV could be used to complement specific coronavirus vaccines, especially in regions of the world where the vaccines are unavailable, and as a stopgap measure for urgent response to future emerging infections. Clinical trial registration number NCT05083039 at clinicaltrals.gov https://clinicaltrials.gov/ct2/show/NCT05083039?term=NCT05083039&draw=2&rank=1.ConclusionsImmunization with bOPV reduced the number of laboratory-confirmed COVID-19 cases, consistent with the original hypothesis that LAVs induce non-specific protection against off-target infections. The findings are in line with previous observations of the protective effects of OPV against seasonal influenza and other viral and bacterial pathogens. The absence of a statistically significant effect on the total number of ARIs may be due to the insufficient number of participants and heterogeneous etiology of ARIs. OPV could be used to complement specific coronavirus vaccines, especially in regions of the world where the vaccines are unavailable, and as a stopgap measure for urgent response to future emerging infections. Clinical trial registration number NCT05083039 at clinicaltrals.gov https://clinicaltrials.gov/ct2/show/NCT05083039?term=NCT05083039&draw=2&rank=1. |
| Author | Karganova, Galina G. Siniugina, Alexandra A. Shustova, Elena Y. Shishova, Anna A. Zheleznov, Lev M. Kozlovskaya, Liubov I. Korduban, Anastasia K. Yagovkina, Nadezhda V. Kovpak, Anastasia A. Khapchaev, Yusuf K. Ishmukhametov, Aydar A. Erovichenkov, Aleksandr A. Pomaskina, Tatiana V. Tsaan, Andrey A. Chumakov, Konstantin Gordeychuk, Ilya V. Piniaeva, Anastasia N. Subbotina, Ksenia A. Ivin, Yury Y. |
| AuthorAffiliation | 4 Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Global Virus Network Center of Excellence , Moscow , Russia 7 Department of Infectious Diseases, Russian Medical Academy of Continuous Professional Education of the Ministry of Health , Moscow , Russia 8 U.S. Food and Drug Administraion (FDA) Office of Vaccines Research and Review, Global Virus Network Center of Excellence , Silver Spring, MD , United States 1 Center for Clinical Trials, Kirov State Medical University, Russian Ministry of Health , Kirov , Russia 6 Biopolis-Kirov 200 Subsidiary of Chumakov Center for Research and Development of Immunobiological Products , Kirov , Russia 5 Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University , Moscow , Russia 2 Department of Epidemiology, Perm State Medical University, Ministry of Health , Perm , Russia 3 RIC-Pharma , Moscow , Russia |
| AuthorAffiliation_xml | – name: 2 Department of Epidemiology, Perm State Medical University, Ministry of Health , Perm , Russia – name: 1 Center for Clinical Trials, Kirov State Medical University, Russian Ministry of Health , Kirov , Russia – name: 4 Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Global Virus Network Center of Excellence , Moscow , Russia – name: 8 U.S. Food and Drug Administraion (FDA) Office of Vaccines Research and Review, Global Virus Network Center of Excellence , Silver Spring, MD , United States – name: 3 RIC-Pharma , Moscow , Russia – name: 7 Department of Infectious Diseases, Russian Medical Academy of Continuous Professional Education of the Ministry of Health , Moscow , Russia – name: 5 Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University , Moscow , Russia – name: 6 Biopolis-Kirov 200 Subsidiary of Chumakov Center for Research and Development of Immunobiological Products , Kirov , Russia |
| Author_xml | – sequence: 1 givenname: Nadezhda V. surname: Yagovkina fullname: Yagovkina, Nadezhda V. – sequence: 2 givenname: Lev M. surname: Zheleznov fullname: Zheleznov, Lev M. – sequence: 3 givenname: Ksenia A. surname: Subbotina fullname: Subbotina, Ksenia A. – sequence: 4 givenname: Andrey A. surname: Tsaan fullname: Tsaan, Andrey A. – sequence: 5 givenname: Liubov I. surname: Kozlovskaya fullname: Kozlovskaya, Liubov I. – sequence: 6 givenname: Ilya V. surname: Gordeychuk fullname: Gordeychuk, Ilya V. – sequence: 7 givenname: Anastasia K. surname: Korduban fullname: Korduban, Anastasia K. – sequence: 8 givenname: Yury Y. surname: Ivin fullname: Ivin, Yury Y. – sequence: 9 givenname: Anastasia A. surname: Kovpak fullname: Kovpak, Anastasia A. – sequence: 10 givenname: Anastasia N. surname: Piniaeva fullname: Piniaeva, Anastasia N. – sequence: 11 givenname: Anna A. surname: Shishova fullname: Shishova, Anna A. – sequence: 12 givenname: Elena Y. surname: Shustova fullname: Shustova, Elena Y. – sequence: 13 givenname: Yusuf K. surname: Khapchaev fullname: Khapchaev, Yusuf K. – sequence: 14 givenname: Galina G. surname: Karganova fullname: Karganova, Galina G. – sequence: 15 givenname: Alexandra A. surname: Siniugina fullname: Siniugina, Alexandra A. – sequence: 16 givenname: Tatiana V. surname: Pomaskina fullname: Pomaskina, Tatiana V. – sequence: 17 givenname: Aleksandr A. surname: Erovichenkov fullname: Erovichenkov, Aleksandr A. – sequence: 18 givenname: Konstantin surname: Chumakov fullname: Chumakov, Konstantin – sequence: 19 givenname: Aydar A. surname: Ishmukhametov fullname: Ishmukhametov, Aydar A. |
| BookMark | eNp9kU1v1DAQhi1UREvpD-CWI5cs8Ucc-1IJLQVWqrQIQTlak_GkdZXYJU6Q-PdkNxWiHPDFlsfvM2M9L9lJTJEYe82rjZTGvu3CMMwbUQmxsVUjFX_GzrjWqpRCqJO_zqfsIuf7alnKSinrF-xU1g3nSokzdnkDiCHCFFIsvofprtiP0BefUx9Ssdao-EJ-RsrFdn-ze19yW-wiBk8R6RV73kGf6eJxP2ffPlx93X4qr_cfd9t31yUuXaay0RW0HIh7L9F6XoPtKhCaI0gpoG08J228Qq-U0bVFrXVtJCo0uq24kOdst3J9gnv3MIYBxl8uQXDHizTeOhingD25tqWFqgSRNMq0tW2hxRpAgjaq6eqFdbmyHuZ2II8Up-XLT6BPKzHcudv001luNW_UAnjzCBjTj5ny5IaQkfoeIqU5O6Ebo4Sx-jA3X5_imHIeqfvThlfuoNEdNbqDRrdqXDLNPxkM01HQMk3o_5P8DVEjox0 |
| CitedBy_id | crossref_primary_10_3389_fpubh_2022_967920 crossref_primary_10_3390_nu16060881 crossref_primary_10_1128_iai_00472_24 crossref_primary_10_1093_ofid_ofac470 crossref_primary_10_3389_fmicb_2022_1016220 crossref_primary_10_34172_aim_31792 crossref_primary_10_7759_cureus_28467 crossref_primary_10_3390_jcm12031154 crossref_primary_10_1016_j_chom_2023_05_004 crossref_primary_10_1080_21645515_2023_2199656 crossref_primary_10_3390_vaccines12030219 crossref_primary_10_1007_s11886_024_02167_7 crossref_primary_10_3390_vaccines11081322 crossref_primary_10_1016_j_jare_2025_09_029 crossref_primary_10_3390_ph16020226 crossref_primary_10_1186_s12879_023_08032_2 crossref_primary_10_1016_j_chom_2023_10_015 crossref_primary_10_1016_S1473_3099_22_00498_4 crossref_primary_10_32388_AZ4JZV_2 crossref_primary_10_3390_tropicalmed9110280 crossref_primary_10_1016_j_it_2025_02_012 crossref_primary_10_3390_vaccines11030655 |
| Cites_doi | 10.1016/S0140-6736(20)31142-9 10.1016/S0140-6736(20)31183-1 10.1016/j.cell.2020.04.042 10.1136/bmj.c6495 10.1371/journal.pone.0265562 10.1093/ije/dyw120 10.1093/cid/civ617 10.1093/cid/cix525 10.1001/jamanetworkopen.2021.35044 10.1016/j.smim.2018.06.002 10.1016/j.clinthera.2020.11.010 10.1016/S1473-3099(19)30742-X 10.1016/S0140-6736(19)31279-6 10.1093/cid/cix354 10.1016/j.vaccine.2009.02.071 10.1001/jama.2020.2648 10.1016/j.cmi.2019.05.024 10.1016/j.vaccine.2021.01.028 10.1016/S0140-6736(20)32541-1 10.1001/jama.2020.12839 10.1016/j.vaccine.2011.09.015 10.1016/j.eclinm.2021.100886 10.1073/pnas.2101718118 10.1016/j.cmi.2019.08.011 10.1038/s41577-020-0285-6 10.1177/003591573102401109 10.1126/science.abc4262 10.1126/science.abc2660 |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 Yagovkina, Zheleznov, Subbotina, Tsaan, Kozlovskaya, Gordeychuk, Korduban, Ivin, Kovpak, Piniaeva, Shishova, Shustova, Khapchaev, Karganova, Siniugina, Pomaskina, Erovichenkov, Chumakov and Ishmukhametov. Copyright © 2022 Yagovkina, Zheleznov, Subbotina, Tsaan, Kozlovskaya, Gordeychuk, Korduban, Ivin, Kovpak, Piniaeva, Shishova, Shustova, Khapchaev, Karganova, Siniugina, Pomaskina, Erovichenkov, Chumakov and Ishmukhametov 2022 Yagovkina, Zheleznov, Subbotina, Tsaan, Kozlovskaya, Gordeychuk, Korduban, Ivin, Kovpak, Piniaeva, Shishova, Shustova, Khapchaev, Karganova, Siniugina, Pomaskina, Erovichenkov, Chumakov and Ishmukhametov |
| Copyright_xml | – notice: Copyright © 2022 Yagovkina, Zheleznov, Subbotina, Tsaan, Kozlovskaya, Gordeychuk, Korduban, Ivin, Kovpak, Piniaeva, Shishova, Shustova, Khapchaev, Karganova, Siniugina, Pomaskina, Erovichenkov, Chumakov and Ishmukhametov. – notice: Copyright © 2022 Yagovkina, Zheleznov, Subbotina, Tsaan, Kozlovskaya, Gordeychuk, Korduban, Ivin, Kovpak, Piniaeva, Shishova, Shustova, Khapchaev, Karganova, Siniugina, Pomaskina, Erovichenkov, Chumakov and Ishmukhametov 2022 Yagovkina, Zheleznov, Subbotina, Tsaan, Kozlovskaya, Gordeychuk, Korduban, Ivin, Kovpak, Piniaeva, Shishova, Shustova, Khapchaev, Karganova, Siniugina, Pomaskina, Erovichenkov, Chumakov and Ishmukhametov |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fimmu.2022.907341 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-3224 |
| ExternalDocumentID | oai_doaj_org_article_bbeca342ee3848b59babc5aa3a6847f5 PMC9196174 10_3389_fimmu_2022_907341 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM 7X8 5PM |
| ID | FETCH-LOGICAL-c442t-760ab1ae1dd3c9d15a9f0a261ca332ab7d1e68d4cd448659c666583c4c86b0123 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 21 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000810963600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1664-3224 |
| IngestDate | Fri Oct 03 12:53:45 EDT 2025 Thu Aug 21 18:35:55 EDT 2025 Sun Nov 09 09:05:39 EST 2025 Tue Nov 18 22:02:33 EST 2025 Sat Nov 29 05:52:21 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c442t-760ab1ae1dd3c9d15a9f0a261ca332ab7d1e68d4cd448659c666583c4c86b0123 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology Edited by: George Kenneth Lewis, University of Maryland, United States Reviewed by: Tibor Bakacs, Alfred Renyi Institute of Mathematics, Hungary; Mihai Netea, Radboud University Nijmegen, Netherlands |
| OpenAccessLink | https://doaj.org/article/bbeca342ee3848b59babc5aa3a6847f5 |
| PMID | 35711442 |
| PQID | 2678428962 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bbeca342ee3848b59babc5aa3a6847f5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9196174 proquest_miscellaneous_2678428962 crossref_primary_10_3389_fimmu_2022_907341 crossref_citationtrail_10_3389_fimmu_2022_907341 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-05-30 |
| PublicationDateYYYYMMDD | 2022-05-30 |
| PublicationDate_xml | – month: 05 year: 2022 text: 2022-05-30 day: 30 |
| PublicationDecade | 2020 |
| PublicationTitle | Frontiers in immunology |
| PublicationYear | 2022 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | De Coster (B32) 2021; 397 Benn (B5) 2020; 20 Oland (B14) 2021; 43 Chumakov (B21) 2021; 118 Chumakov (B20) 2020; 368 Sutter (B29) Gyssens (B7) 2019; 25 Nielsen (B13) 2021; 36 Upfill-Brown (B18) 2017; 65 Voroshilova (B17) 1989; 36 Minor (B30) 2009; 27 Van Damme (B31) 2019; 394 Wu (B1) 2020; 323 Chu (B2) 2020; 395 Rieckmann (B12) 2017; 46 Sorup (B15) 2021; 40 Seppala (B19) 2011; 29 (B24) 1997 Netea (B27) 2020; 181 Chumakov (B16) 1992 Dominguez-Andres (B25) 2020; 368 Netea (B26) 2020; 20 Habibzadeh (B23) 2021; 4 MacIntyre (B3) 2020; 395 Lund (B11) 2015; 61 Aaby (B28) 2019; 25 Habibzadeh (B22) 2021; 17 Wiersinga (B4) 2020; 324 de Bree (B6) 2018; 39 Biering-Sorensen (B9) 2017; 65 Aaby (B10) 2010; 341 Calmette (B8) 1931; 24 |
| References_xml | – volume-title: Manual for Virological Investigation of Poliomyelitis year: 1997 ident: B24 – volume: 395 year: 2020 ident: B2 article-title: Physical Distancing, Face Masks, and Eye Protection to Prevent Person-To-Person Transmission of SARS-CoV-2 and COVID-19: A Systematic Review and Meta-Analysis publication-title: Lancet doi: 10.1016/S0140-6736(20)31142-9 – volume: 395 year: 2020 ident: B3 article-title: Physical Distancing, Face Masks, and Eye Protection for Prevention of COVID-19 publication-title: Lancet doi: 10.1016/S0140-6736(20)31183-1 – volume-title: 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy ident: B29 article-title: Vaccine-Associated Paralytic Poliomyelitis Among Immune Deficient Persons (iVAPP): An Emerging Problem in the United States – volume: 181 year: 2020 ident: B27 article-title: Trained Immunity: A Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection publication-title: Cell doi: 10.1016/j.cell.2020.04.042 – volume: 341 start-page: c6495 year: 2010 ident: B10 article-title: Non-Specific Effects of Standard Measles Vaccine at 4.5 and 9 Months of Age on Childhood Mortality: Randomised Controlled Trial publication-title: Bmj doi: 10.1136/bmj.c6495 – volume: 17 year: 2021 ident: B22 article-title: Use of Oral Polio Vaccine and the Incidence of COVID-19 in the World publication-title: PloS One doi: 10.1371/journal.pone.0265562 – volume: 46 start-page: 695 year: 2017 ident: B12 article-title: Vaccinations Against Smallpox and Tuberculosis Are Associated With Better Long-Term Survival: A Danish Case-Cohort Study 1971-2010 publication-title: Int J Epidemiol doi: 10.1093/ije/dyw120 – volume: 61 year: 2015 ident: B11 article-title: The Effect of Oral Polio Vaccine at Birth on Infant Mortality: A Randomized Trial publication-title: Clin Infect Dis doi: 10.1093/cid/civ617 – volume: 65 year: 2017 ident: B9 article-title: Early BCG-Denmark and Neonatal Mortality Among Infants Weighing <2500 G: A Randomized Controlled Trial publication-title: Clin Infect Dis doi: 10.1093/cid/cix525 – volume: 4 start-page: e2135044 year: 2021 ident: B23 article-title: COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2021.35044 – volume: 39 start-page: 35 year: 2018 ident: B6 article-title: Non-Specific Effects of Vaccines: Current Evidence and Potential Implications publication-title: Semin Immunol doi: 10.1016/j.smim.2018.06.002 – volume: 43 start-page: 172 year: 2021 ident: B14 article-title: Reduced Mortality After Oral Polio Vaccination and Increased Mortality After Diphtheria-Tetanus-Pertussis Vaccination in Children in a Low-Income Setting publication-title: Clin Ther doi: 10.1016/j.clinthera.2020.11.010 – volume: 20 year: 2020 ident: B5 article-title: Vaccinology: Time to Change the Paradigm publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(19)30742-X – volume: 394 year: 2019 ident: B31 article-title: The Safety and Immunogenicity of Two Novel Live Attenuated Monovalent (Serotype 2) Oral Poliovirus Vaccines in Healthy Adults: A Double-Blind, Single-Centre Phase 1 Study publication-title: Lancet doi: 10.1016/S0140-6736(19)31279-6 – volume: 65 year: 2017 ident: B18 article-title: Nonspecific Effects of Oral Polio Vaccine on Diarrheal Burden and Etiology Among Bangladeshi Infants publication-title: Clin Infect Dis doi: 10.1093/cid/cix354 – volume: 27 year: 2009 ident: B30 article-title: Vaccine-Derived Poliovirus (VDPV): Impact on Poliomyelitis Eradication publication-title: Vaccine doi: 10.1016/j.vaccine.2009.02.071 – volume: 323 year: 2020 ident: B1 article-title: Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention publication-title: JAMA doi: 10.1001/jama.2020.2648 – volume: 25 year: 2019 ident: B7 article-title: Heterologous Effects of Vaccination and Trained Immunity publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2019.05.024 – volume: 40 year: 2021 ident: B15 article-title: Revaccination With Measles-Mumps-Rubella Vaccine and Hospitalization for Infection in Denmark and Sweden - An Interrupted Time-Series Analysis publication-title: Vaccine doi: 10.1016/j.vaccine.2021.01.028 – volume: 397 start-page: 39 year: 2021 ident: B32 article-title: Safety and Immunogenicity of Two Novel Type 2 Oral Poliovirus Vaccine Candidates Compared With a Monovalent Type 2 Oral Poliovirus Vaccine in Healthy Adults: Two Clinical Trials publication-title: Lancet doi: 10.1016/S0140-6736(20)32541-1 – volume: 324 year: 2020 ident: B4 article-title: Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review publication-title: JAMA doi: 10.1001/jama.2020.12839 – volume: 29 year: 2011 ident: B19 article-title: Viral Interference Induced by Live Attenuated Virus Vaccine (OPV) can Prevent Otitis Media publication-title: Vaccine doi: 10.1016/j.vaccine.2011.09.015 – volume: 36 start-page: 100886 year: 2021 ident: B13 article-title: National Immunisation Campaigns With Oral Polio Vaccine may Reduce All-Cause Mortality: Analysis of 2004-2019 Demographic Surveillance Data in Rural Bangladesh publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2021.100886 – volume: 118 year: 2021 ident: B21 article-title: Old Vaccines for New Infections: Exploiting Innate Immunity to Control COVID-19 and Prevent Future Pandemics publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.2101718118 – volume: 25 year: 2019 ident: B28 article-title: Developing the Concept of Beneficial Non-Specific Effect of Live Vaccines With Epidemiological Studies publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2019.08.011 – start-page: 37 year: 1992 ident: B16 article-title: [Live Enteroviral Vaccines for the Emergency Nonspecific Prevention of Mass Respiratory Diseases During Fall-Winter Epidemics of Influenza and Acute Respiratory Diseases] publication-title: Zhurnal Mikrobiol Epidemiol i Immunobiol / – volume: 20 year: 2020 ident: B26 article-title: Defining Trained Immunity and Its Role in Health and Disease publication-title: Nat Rev Immunol doi: 10.1038/s41577-020-0285-6 – volume: 24 year: 1931 ident: B8 article-title: Preventive Vaccination Against Tuberculosis With BCG publication-title: Proc R Soc Med doi: 10.1177/003591573102401109 – volume: 368 year: 2020 ident: B20 article-title: Can Existing Live Vaccines Prevent COVID-19 publication-title: Science doi: 10.1126/science.abc4262 – volume: 36 start-page: 191 year: 1989 ident: B17 article-title: Potential Use of Nonpathogenic Enteroviruses for Control of Human Disease publication-title: Prog Med Virol – volume: 368 year: 2020 ident: B25 article-title: The Specifics of Innate Immune Memory publication-title: Science doi: 10.1126/science.abc2660 |
| SSID | ssj0000493335 |
| Score | 2.4380083 |
| Snippet | Effective response to emerging pandemic threats is complicated by the need to develop specific vaccines and other medical products. The availability of broadly... BackgroundEffective response to emerging pandemic threats is complicated by the need to develop specific vaccines and other medical products. The availability... |
| SourceID | doaj pubmedcentral proquest crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 907341 |
| SubjectTerms | emerging diseases Immunology innate immunity non-specific protection SARS-CoV-2 vaccine off-target effects |
| Title | Vaccination With Oral Polio Vaccine Reduces COVID-19 Incidence |
| URI | https://www.proquest.com/docview/2678428962 https://pubmed.ncbi.nlm.nih.gov/PMC9196174 https://doaj.org/article/bbeca342ee3848b59babc5aa3a6847f5 |
| Volume | 13 |
| WOSCitedRecordID | wos000810963600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB5RVKReqtIWsaWsXIlTpZTETvy4ILULiEo8qqqFvVl-RQRBFrG7SFz62xnHC9pc2ksvOSSTxPkmtueLJ98A7NDc8NoG7N-BIkHx0mY2SJZJF4TPubUh_Sh8LE5P5XisfiyV-oo5YUkeOAG3i9bOsJKGwGQpbaWssa4yhhmOA2vdqZfmQi2RqasU9zLGqrSMiSxM7dbNzc0c-SClX5APsrLoTUSdXn8vyOynSC7NOYdv4PUiWCRfUyPXYSW0b2EtlY98eAd758a5Jn3OIxfN7JKc4UVITGmbkHQskJ9RmzVMyejs_Pt-ViiCI0IqJPoefh8e_BodZYt6CJkrSzrLBM-NLUwovGdO-aIyqs4NUiAEiFFjhS8Cl750HjkXr5RDalJJ5konuY2x0wastpM2bAIRjKOlwM6MFKk2VHqjnMVopUaoPSsHkD-Bo91CLDzWrLjWSBoinrrDU0c8dcJzAJ-fT7lNShl_M_4WEX82jCLX3Q50vV64Xv_L9QP49OQvjZ0irnSYNkzmU01xCkZepTgdgOg5snfH_pG2uezktRUOSsjTPvyPJm7Bq_jUXbpB_hFWZ3fzsA0v3f2smd4N4YUYy2H35uL25M_BIxoD9Vg |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vaccination+With+Oral+Polio+Vaccine+Reduces+COVID-19+Incidence&rft.jtitle=Frontiers+in+immunology&rft.au=Yagovkina%2C+Nadezhda+V.&rft.au=Zheleznov%2C+Lev+M.&rft.au=Subbotina%2C+Ksenia+A.&rft.au=Tsaan%2C+Andrey+A.&rft.date=2022-05-30&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=13&rft_id=info:doi/10.3389%2Ffimmu.2022.907341&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2022_907341 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |